Interleukin 13 receptor ␣ 2 (IL-13R ␣ 2) chain is highly expressed on some tumor cell lines and primary cell cultures. This receptor chain plays an important role in ligand binding and internalization. To determine the functional significance of overexpression of this chain, we stably transfected IL-13R ␣ 2 chain in human breast (MDA-MB-231) and pancreatic (PANC-1) cancer cell lines that naturally do not express this chain. There was no difference in growth between vector only transfected and IL-13R ␣ 2 chain transfected cells in vitro. However, surprisingly, in immunodeficient mice, tumorigenicity was profoundly inhibited in IL-13R ␣ 2 chain overexpressing tumors. Because breast tumors that grew later showed loss of IL-13R ␣ 2 gene expression, lack of tumorigenicity correlated positively with IL-13R ␣ 2 chain expression. Inflammatory cells including neutrophils and macrophages were identified in IL-13R ␣ 2 overexpressing regressing tumors and neutrophils were found to produce IL-13. IL-13 showed a modest antitumor activity to IL-13R ␣ 2 chain overexpressing tumors in vitro and in vivo. Furthermore, IL-13R ␣ 2 chain overexpressing tumors constitutively produced IL-8 that has been shown to have antitumor effect. These results establish a novel function of a cytokine receptor chain and further suggest that the presence of this chain on tumor cells by itself may play a key role in tumorigenicity.
Introduction
IL-13 is a Th2 cell-derived pleiotropic immune regulatory cytokine (1) . It has predominant biological activities on B cells and monocytes. In recent years, the receptors for IL-13 (IL-13R) have been extensively characterized. We have demonstrated that IL-13R may exist as three different forms in different cell types (2) (3) (4) (5) (6) (7) . Two different chains of the IL-13R, IL-13R ␣ 1 (also known as IL-13R ␣Ј ) and IL-13R ␣ 2 (also known as IL-13R ␣ ) have been cloned. The murine and human IL-13R ␣ 1 chain was cloned first (8, 9) . This chain binds IL-13 at low level but when coupled with IL-4R ␣ chain (also known as IL-4R ␤ ) binds IL-13 with high affinity and mediates IL-13-induced signaling (8) (9) (10) . The second chain of IL-13R, IL-13R ␣ 2 was cloned from a human renal cell carcinoma cell line (Caki-1). This chain has 50% homology to IL-5R at the DNA level, has a short intracellular domain, and binds IL-13 with ‫ف‬ 50 times higher affinity than IL-13R ␣ 1 chain (11, 12) .
We and others have reported that IL-13R ␣ 2 chain is expressed on many human cancer cell lines and primary cell cultures including glioblastoma, AIDS-associated Kaposi's sarcoma, ovarian carcinoma, renal cell carcinoma (13) (14) (15) (16) , and fibroblast cell lines (6) . Interestingly, this receptor chain does not seem to be present or present at extremely low level in normal endothelial cells, immune cells, or certain types of cancer cell lines as assessed by RT-PCR analysis (12) (13) (14) (15) . The reason for difference in the expression is unknown; however, it is predicted that some correlation between the presence of IL-13R ␣ 2 chain and tumor biology must exist. More recently, we have demonstrated that IL-13R ␣ 2 chain plays an important role in IL-13 binding and internalization (17) (18) (19) . Although the function of IL-13R ␣ 2 chain is being unraveled, it is still 1744 Gene Transfer of IL-13R ␣ 2 Chain Inhibits Tumorigenicity In Vivo not known why this receptor chain is expressed on the surface of only certain tumor cell lines. Numerous studies in the literature suggest that gene transfer of cytokine or growth factors in tumor cells can inhibit tumorigenicity of murine or human tumors in experimental animals (20) (21) (22) (23) (24) (25) . In most studies, resident immune cells seemed to play a major role in the loss of tumorigenesis in vivo (20, 21, (23) (24) (25) (26) . However, several studies have reported that in addition to immune mechanism, in some situations, inflammatory cells such as eosinophils and macrophages play a dominant role in the control of tumor growth (24, 25) . Although the mechanism of tumor growth control by inflammatory cells is not completely clear, the growth factor(s) or chemokine(s) produced by these cells may play some role in this process (26) (27) (28) . One of the chemokine, IL-8, has been shown to play a major role in the control of tumorigenesis most likely through regulation of angiogenesis in developing tumor (20, 21, 26) . Despite extensive studies on the role of growth factors, cytokines, and chemokines on tumorigenesis, the role of receptors for these factors has not been extensively studied.
In this study, we have examined the functional significance of IL-13R ␣ 2 chain in two tumor models. We stably transfected human breast cancer cell line, MDA-MB-231 and pancreatic cancer cell line, PANC-1 with IL-13R ␣ 2 chain. Various clones of these cell lines were assessed for IL-13 receptor expression in vitro and in vivo, and the effect of IL-13R ␣ 2 chain on tumorigenicity of these two tumorigenic tumor cell lines was investigated. To our surprise, we found that the overexpression of IL-13R ␣ 2 chain profoundly inhibited tumor development in immunodeficient animals. The mechanism of tumor regression in these two tumor models has been investigated.
Materials and Methods
Recombinant Cytokine, Toxin, and Cell Lines. Recombinant human IL-4 and IL-13 were produced and purified to homogeneity in our laboratory (29) . Recombinant IL-13-Pseudomonas exotoxin A (PE) * 38QQR was also produced and purified in our laboratory (30, 31) . Human breast cancer (MDA-MB-231) and pancreatic cancer (PANC-1) cell lines were purchased from the American Type Culture Collection. Cells were cultured in RPMI 1640 (MDA-MB-231) or DMEM (PANC-1) containing 10% FBS (Biowhittaker), 1 mM Hepes, 1 mM L -glutamine, 100 g/ml penicillin, and 100 g/ml streptomycin (Biowhittaker). Stable Transfection and Selection. cDNA encoding human IL-13R ␣ 2 chain was cloned into pME18S mammalian expression vector (11, 32) . Plasmid DNA (12 g/100-mm culture dish) was cotransfected with 1.2 g of pPUR selection vector (CLON-TECH) into semiconfluent cells using GenePORTER transfection reagent (Gene Therapy Systems) according to the manufacturer's instructions. Briefly, cells (2 ϫ 10 6 cells per 100-mm dish) were incubated with the DNA-GenePORTER mixture for 5 h in DMEM followed by 20-h incubation in fresh DMEM containing 20% FBS and additional 24 h in medium with 10% FBS. At 48 h after the start of transfection, cells were trypsinized and cultured in selection medium that contained 1 g/ml of puromycin (CLONTECH). Cells were maintained for 4 wk in the same medium, which was replaced every 3 d. Resistant clones isolated with the cloning cylinder (Bel-Art Products) were characterized for IL-13R ␣ 2 chain expression by RT-PCR and radioreceptor binding assays. Finally, three IL-13R ␣ 2-overexpressing clones (termed ␣ 2 clone 1, 2, and 3) were selected for further analysis. The vector control (mock) transfected cell lines were used for comparison with IL-13R ␣ 2 transfected cells. To reduce antibiotic side effects, puromycin was removed at least 14 d before experiments were performed.
RT-PCR. To detect the mRNA expression in cells, total RNA was isolated using TRIZOL reagent (Life Technologies), then RT-PCR was performed using specific primers as described previously (13, 33) .
Radioreceptor Binding Assays. Recombinant human IL-13 was labeled with 125 [I] (Amersham Pharmacia Biotech) using IODO-GEN reagent (Pierce Chemical Co.) as described previously (34) . The specific activity of the radio-labeled cytokines was estimated to be 12.7 Ci/ g of protein.
For binding experiments, 5 ϫ 10 5 cells in 100 l binding buffer (RPMI 1640 containing 0.2% human serum albumin and 10 mM Hepes) were incubated with 200 pM 125 [I]-IL-13 with or without various concentrations (10 pM to 100 nM) of unlabeled IL-13 at 4 Њ C for 2 h. Cellbound 125 [I]-IL-13 was separated from unbound by centrifugation through a phthalate oil gradient and radioactivity was determined with a ␥ counter (Wallac). In some experiments, the number of IL-13Rs and binding affinities were calculated using the LIGAND program (35) .
Protein Synthesis Inhibition Assay. The cytotoxic activity of IL-13 toxin was tested as described previously (36) . Typically, 10 4 cells were cultured in leucine-free medium with or without various concentrations of IL-13-PE38QQR for 20-22 h at 37 Њ C. In general, five mice were used for each group. In some experiments, mice were injected with 1 g of IL-13 intratumorally or 0.1 mg of Gr-1 (rat anti-mouse granulocytes antibody; Cedarlane) intraperitoneally.
Histological Analysis. Tissues at the site of tumor injection were embedded in OCT compound (Miles) and snap frozen by liquid nitrogen. 5-cryostat sections were fixed in 90% ethyl alcohol and stained with hematoxylin and eosin.
Immunofluorescence Assay. Sections (5 m) were prepared and stained for neutrophils (Gr-1; BD PharMingen), macrophage (Mac-3; BD PharMingen), or IL-13 (C-19; Santa Cruz Biotechnology, Inc.). Isotype control Abs was used for each corresponding Ab. Slides were fixed in acetone at Ϫ 20 Њ C for 5 min and air dried. Nonspecific binding was blocked by treatment with 10% serum (goat or rat) for 1 h followed by incubation with Ab or isotype control. Sections were subsequently incubated for 1 h with secondary Ab that had either tetramethylrhodamine isothiocyanate or FITC tag. After three washes with PBS, slides were dried and layered with Vectashield antifluorescence fading mounting medium (Vector Laboratories) and a coverslip. The slides were viewed in a Nikon fluorescence microscope using appropriate filters.
Clonogenic Assay. The in vitro antitumor activity of IL-13 on MDA-MB-231 and PANC-1 cells transfected with IL-13R ␣ 2 chain or vector only (mock control) was determined by a colonyforming assay as described previously (18) .
ELISA 
Results

IL-13R ␣ 2 Expression in MDA-MB-231 and PANC-1 Cell Lines.
To determine the expression of IL-13R in MDA-MB-231 and PANC-1 cell lines, we first examined the mRNA expression of IL-13R components, IL-13R ␣ 2 and IL -13R ␣ 1 chains by RT-PCR. As shown in Fig. 1 , mRNA for IL-13R ␣ 1 chain was present in both cell lines, however they did not express IL-13R ␣ 2 mRNA. In stably transfected cell lines, IL-13R ␣ 2 chain expression was confirmed as these clones expressed abundant mRNA for this chain. PM-RCC cells that express IL-13R ␣ 2 and IL-13R ␣ 1 mRNA served as a positive control (13) . To determine the in vitro stability of gene expression, we cultured vector only transfected control cells and IL-13R␣2 chain transfected cells (MDA-MB-231␣2 clone 3 and PANC-1␣2 clone 2) for a 90-d period after removal of antibiotics. During the culture, cells were split twice (MDA-MB-231) or once (PANC-1) a week. At various time points, total RNA was extracted and mRNA expression for IL-13R␣2 chain was assessed by RT-PCR. In MDA-MB-231␣2 clone, IL-13R␣2 gene expression decreased in a time-dependent manner, and on day 90 very faint mRNA expression was detected (Fig. 4 A) . However, in case of PANC-1␣2 clone, IL-13R␣2 chain expression remained at high level until day 90, suggesting this clone expresses this chain very stably.
IL-13 Binding Sites on MDA-MB-231 and PANC-1 Cells Increased After Gene Transfer of IL-13R
To further confirm the expression of IL-13R␣2 chain on plasma membranes of cells transfected with this chain, we used a chimeric protein composed of IL-13 and a truncated form of PE, IL-13 toxin (IL-13-PE38QQR). This molecule was found to be potently cytotoxic to IL-13R-positive solid tumor cells (30, 31, (38) (39) (40) . It has been found that IL-13 toxin will only bind and be cytotoxic to cells that express high levels of IL-13R on cell surface. As shown in Fig. 4 B, just after removal of antibiotic, in both MDA-MB-231 and PANC-1 cells, cytotoxic activity of IL-13 toxin dramatically increased after gene transfer of IL-13R␣2 chain. IC 50 (the protein concentration required for the inhibition of protein synthesis by 50%) in MDA-MB- were cultured with various concentrations of IL-13-PE38QQR (0-1,000 ng/ml) with or without IL-4 or IL-13 (2 g/ml). The results were represented as means Ϯ SD (n ϭ 4). The concentration of IL-13-PE38QQR causing 50% inhibition of protein synthesis was calculated (IC 50 ).
231 and PANC-1 cell lines decreased from Ͼ1,000 ng/ml to 0.25 ng/ml and from 60 ng/ml to Ͻ0.1 ng/ml, respectively. These cytotoxic activities in cells transfected with IL-13R␣2 chain were neutralized by IL-13 not by IL-4, indicating the cytotoxicity mediated by IL-13 toxin is specific. The stability of IL-13R␣2 chain expression in MDA-MB-231 and PANC-1 cells transfected with this chain was also assessed by determining cytotoxicity mediated by IL-13 toxin using cells cultured for same period as Fig. 4 A. As shown in Fig. 4 C, IC 50 s increased in a time-dependent manner in MDA-MB-231 cells transfected with IL-13R␣2 chain. However, IC 50 remained significantly lower than observed in vector only transfected cells (Fig. 4 B) . On day 90, the IC 50 increased to ‫57ف‬ ng/ml correlating with significant decrease in IL-13R␣2 gene expression. On the other hand, PANC-1 cells transfected with IL-13R␣2 chain maintained high sensitivity to IL-13 toxin throughout the 90-d period (Ͻ1 ng/ml). These results were consistent with RT-PCR results (Fig. 4 A) To assess the in vivo stability of IL-13R␣2 chain expression, MDA-MB-231 and PANC-1 tumors were resected at various time points (MDA-MB-231, days 14, 53, and 90) or on day 90 (PANC-1; vector only transfected control and IL-13R␣2 chain transfected clones that had very small tumors). Tumors were minced and treated with 10 g/ml collagenase, 1 mg/ml hyaluronidase, and 0.5 mg/ml DNase (Sigma-Aldrich), washed with PBS for two times and cultured in culture medium containing 10% FBS. After three passages, contaminating tumor debris and blood cells were removed, and then total RNA was extracted and mRNA expression for IL-13R␣2 chain was assessed by RT-PCR. As shown in Fig. 5 B, in MDA-MB-231 tumors derived from IL-13R␣2 chain transfected clone 3, the expression To further analyze the IL-13R␣2 chain expression on resected tumors, using three-passage-cultured cells, cytotoxic activity of IL-13 toxin was examined. As shown in Fig. 5 C, cells derived from MDA-MB-231 tumors (IL-13R␣2 chain transfectants clone 3) showed the decreasing sensitivities to IL-13 toxin in a time-dependent manner. On day 90, when IL-13R␣2 gene expression was significantly diminished, the IC 50 rose to ‫052ف‬ ng/ml. The IC 50 still remained at least four times lower compared with vector only transfected control cells (IC 50 Ͼ 1,000 ng/ ml). Cells cultured from PANC-1 IL-13R␣2 chain transfected clones-derived tumors on day 90 showed significantly less sensitivity to IL-13 toxin compared with in vitro cultured PANC-1 IL-13R␣2 chain transfected cells (IC 50 Ͻ 1 ng/ml; Fig. 4 C) , and the IC 50 ranged between 27 and 42 ng/ml. Sensitivity of PANC-1 cells cultured from vector only transfected control clone-derived tumor to IL-13 toxin was similar to IL-13R␣2 chain transfected clones-derived tumors (IC 50 ϭ 45 ng/ml). These results were consistent with RT-PCR results and indicate that loss of IL-13R␣2 chain in vivo correlated with loss in sensitivity to IL-13 toxin.
Infiltration of Inflammatory Cells Was Observed at Early Time Point After Implantation of MDA-MB-231 Tumors
Overexpressing IL-13R␣2 Chain. To investigate the mechanism by which tumorigenicity of IL-13R␣2 chain transfected tumors was inhibited, both vector-only transfected and IL-13R␣2 chain transfected MDA-MB-231 tumors were resected from mice on days 3, 5, 8, and 35 after the implantation, and then histological study of the tumor was performed after H&E staining. As shown in Fig. 6 A, vector-only transfected control cells developed breast tumors without infiltration of inflammatory cells. On the other hand, MDA-MB-231 tumor transfected with IL-13R␣2 chain displayed a marked cellularity (Fig. 6 B and  C) . The cell infiltration was dominant in connective tissue around the tumor on day 3, however, as the time progressed (days 5 and 8), inflammatory cells were observed infiltrating inside the tumor mass. Both vector-only and IL-13R␣2 chain transfected tumors resected on day 35 displayed limited level of inflammatory cells. PANC-1 tumors could not be analyzed on days 8 and 35 because tumor had completely regressed. The population of infiltrating cells differed among tumors, and neutrophils were determined to be dominant cell type (Table I) .
Immunofluorescence Assays Showed Production of IL-13 from Neutrophils in IL-13R␣2 Chain Overexpressing Tumors.
To further characterize the infiltrating cells, immunofluorescence assays were performed on frozen tissue sections ob- . Interestingly, we found colocalization of IL-13 and neutrophils but not macrophages which indicates that IL-13 is produced from neutrophils (Fig. 7 D) .
On the other hand, macrophages did not produce IL-13. These results suggest that infiltrating neutrophils are most probably involved in the inhibition of tumorigenicity by gene transfer of IL-13R␣2 chain.
IL-13 Showed Modest Antitumor Activity in IL-13R␣2 Chain Overexpressing Tumors In Vitro and In Vivo.
Because IL-13 production from neutrophils was observed in IL-13R␣2 overexpressing tumors, we hypothesized that IL-13 itself may have direct antitumor effect or is involved in the inhibition of tumorigenicity. To address this issue, we first performed in vitro colony formation assay in MDA-MB-231 and PANC-1 cells transfected with vector only (mock control) or IL-13R␣2 chain. As shown in Fig.  8 A, in both cell lines, IL-13 showed a modest inhibitory effect on colony formation in IL-13R␣2 transfectants (50% inhibition in MDA-MB-231 cells and 28% inhibition in PANC-1 cells at 50-500 ng/ml of IL-13). Although IL-13 showed slight inhibitory effect on colony formation in mock control MDA-MB-231 cells, the effect was more pronounced in IL-13R␣2 transfectants.
To assess in vivo antitumor effect of IL-13 in IL-13R␣2 overexpressing tumors, we then directly injected IL-13 (1 g) in MDA-MB-231 tumor (mock control and IL-13R␣2 transfectants) bearing nude mice intratumorally from days 4 to 8 (total five injections). As shown in Fig. 8 B, in control tumors, IL-13 did not show significant effect and tumors grew as fast as tumors without any IL-13 injections (Fig. 5 A) . On the other hand, in IL-13Ra2 overexpressing tumors, IL-13 induced regression of tumors during the injection period, and two out of five tumors were completely disappeared by day 33. Although in the rest of the mice tumors started growing eventually, the mean size of the tumors remained very small (28 mm 2 ) compared with excipient-injected control tumors (207 mm 2 ) by day 83 after implantation of the tumors. These results suggest that IL-13 produced by neutrophils should be considered to play a role in the inhibition of tumorigenesis in vivo in IL-13R␣2 chain overexpressing tumors.
Depletion of Neutrophils in IL-13R␣2 Chain Overexpressing Tumor Bearing Nude Mice Showed Initial Growth of Tumors.
To assess whether neutrophils by itself may have some potential role in the inhibition of tumor growth, we depleted neutrophil in nude mice by intraperitoneal injections of antineutrophil antibody (Gr-1) and IL-13R␣2 chain transfected MDA-MB-231 cells were implanted. During the injection period, blood samples were taken from mice and absence of neutrophils was confirmed (data not shown). As shown in Fig. 9 , during the depletion period IL-13R␣2 chain transfected tumor grew better than excipient-only injected tumors. These tumors kept on growing by day 14 after implantation, then began to regress once antibody injection was stopped. Finally, these tumors regressed to the mean tumor size of control IL-13R␣2 tumors (20-23 mm 2 ) when the experiment was terminated. These data indicate that neutrophils play a partial role in the inhibition of tumor growth.
High Levels of IL-8 Was Constitutively Released from IL-13R␣2 Chain Overexpressing MDA-MB-231 Tumor Cells.
IL-8 has been shown to have potent antitumor effect in several tumor types including lung cancer, ovarian cancer, and prostate cancer (20, 21) . To explore whether this chemokine is released from IL-13R␣2 chain overexpressing tumor cells, we extracted RNA from MDA-MB-231 cells transfected with vector only (mock control) or IL-13R␣2 chain after treatment with IL-13 (50 ng/ml) for 24 h. By serial twofold dilutions of RNA samples, we found that IL-8 gene is constitutively expressed in MDA-MB-231 mock control cells, and approximately fourfold upregulation of this gene was observed after stimulation with IL-13 ( Fig.  10 A) . To our surprise, in IL-13R␣2 chain transfected MDA-MB-231 cells, IL-8 gene expression was two-to fourfold higher compared with mock control cells. To further confirm these results, we performed ELISA assays for human IL-8 in MDA-MB-231 derived culture supernatants. As shown in Fig. 10 B, after stimulation with IL-13 (50 ng/ ml), IL-8 production from the mock control cells was increased in a time-dependent manner. In IL-13R␣2 chain transfected MDA-MB-231 cells, constitutive release of IL-8 was ‫-57.1ف‬fold higher compared with mock control cells. IL-8 release level from IL-13R␣2 chain transfectants was also augmented in a time-dependent manner. These results suggest that IL-8 is constitutively produced from IL-13R␣2 chain overexpressing tumor cells and this production level is upregulated after stimulation with IL-13.
Discussion
In this study, we demonstrate that overexpression of IL-13R␣2 chain inhibits tumorigenicity of human breast and pancreatic tumor cells in nude mice. Although there was no difference in growth between vector only transfected cells and IL-13R␣2 chain transfected cells in vitro, in nude mice, tumorigenicity was impaired in IL-13R␣2 chain overexpressing tumors. The presence of inflammatory cells, particularly neutrophils were found to correlate with the lack of tumorigenicity or significant reduction in tumor growth rate. Neutrophils were found to produce IL-13 and IL-13 had modest antitumor effect in IL-13R␣2 overexpressing tumors. Moreover, IL-13R␣2 overexpressing tumor cells produced high level of IL-8 which has been shown to reduce tumorigenicity in several tumor models. To our knowledge this is the first report that implicates cytokine receptor chain in tumorigenesis.
It is of interest to note that stability of IL-13R␣2 chain expression and tumor growth in nude mice correlated extremely well. MDA-MB-231 tumors transfected with IL-13R␣2 chain did not begin to grow until ‫ف‬day 50, after which they grew gradually. To reveal the mechanism by which IL-13R␣2 chain inhibited tumorigenicity in MDA-MB-231 and PANC-1 tumors, we performed histological examinations and immunofluorescence assays. We observed infiltration of inflammatory cells, particularly neutrophils and macrophages during early period of slow tumor growth suggesting that these cells may play an important role in the inhibition of tumorigenicity caused by overexpression of IL-13R␣2 chain. Moreover, we found that infiltrated neutrophils produced IL-13 that had modest antitumor effect on IL-13R␣2 chain overexpressing tumor in vitro and in vivo. IL-13 has been shown to be produced by B cells, T cells, and monocytes (41) . Infiltrating inflammatory cells also produce Th2 cytokines (42, 43) . In addition IL-13 has been shown to inhibit in vitro growth of renal cell carci- noma and breast tumor cells (44, 45) . Gene transfer of IL-13 in tumor cells has been shown to inhibit tumorigenicity of mastocytoma cells in animal model (22) . Thus, these reports support our findings that IL-13 secreted by infiltrating inflammatory cells may at least partially inhibit tumor growth of IL-13R␣2 chain overexpressing tumors. We also observed rapid initial growth of IL-13R␣2 chain transfected tumor in neutrophil depleted mice similar to control mice, and when administration of antineutrophil antibody stopped, the tumor growth decreased similar to nonneutrophil depleted mice. Because neutrophils, particularly polymorphonuclear leukocytes are known to enhance antitumor immune responses against cancers (23, 46, 47) , neutrophils along with IL-13 may play some role in the inhibition of growth of IL-13R␣2 chain overexpressing tumors. Alternatively, IL-13 produced by neutrophils may induce additional factor(s) from tumor cells that may further inhibit tumor growth of IL-13R␣2 chain overexpressing tumors.
We found high level of IL-8 production from IL-13R␣2 chain overexpressing MDA-MB-231 cells. IL-8 has been shown to regulate angiogenesis and matrix metalloproteinase 9 (MMP-9) productions in tumors consequently reducing tumorigenicity and metastatic potential (20, 21) . It is therefore possible that IL-8 secreted by IL-13R␣2 chain overexpressing tumor cells results in the regulation of tumorigenicity. However, Arenberg et al. observed that by injecting neutralizing antibody to IL-8 in SCID mice results in regression of non-small cell lung cancer tumor xenografts (26) . Thus, IL-8 can produce contrasting effect in different tumor models. In our RT-PCR and ELISA results, IL-13 was found to further augment IL-8 expression in IL-13R␣2 transfected tumors. Taken together, our results suggest that the mechanism involved in the loss of in vivo tumorigenicity of IL-13R␣2 chain overexpressing tumor cells involve infiltration of IL-13 producing neutrophils which in turn augment IL-8 production from tumor cells for an autocrine growth inhibition.
Although there seems to be no reports that show inhibition of tumorigenicity by overexpression of one cytokine receptor subunit on the cell surface, it has been reported that some cell-surface antigens, e.g., a proliferation-inducing ligand (APRIL), heregulin (HRG), and transforming growth factor ␤ inhibit tumorigenesis in certain types of cancers (48) (49) (50) . Furthermore, cytokines like IL-4, IL-8, and IL-13 produced by inflammatory cells such as neutrophils, macrophages, and/or eosinophils have been shown to inhibit tumorigenesis (20-22, 24, 25, 42) . Our results also suggest involvement of infiltrating inflammatory cells in the inhibition of tumorigenesis caused by IL-13R␣2 chain overexpression. In our previous studies, we generated several IL-13R␣2 chain transfected cancer cell clones including head and neck and prostate cancer cells, however, in vivo tumorigenicity was not impaired in these cases (31, 40) . Because IL-13R␣2 chain expression level was lower in these cases, it is possible that the loss of tumorigenicity by IL-13R␣2 chain overexpression depends on the IL-13R␣2 expression level. Alternatively, various tumor types behave differently. These possibilities are being investigated.
The significance of constitutive expression of IL-13R␣2 chain in certain tumor cell types is still not known. In murine model, extracellular domain of IL-13R␣2 chain is secreted by cells and has been detected in serum and urine of mice. However, extracellular domain of this chain has not been detected in body fluids of humans (12) . Based on murine studies it has been proposed that extracellular domain of IL-13R␣2 chain serves as a decoy and possibly a IL-13 carrier protein. In contrast, here we show a unique function of IL-13R␣2 chain which inhibits tumorigenicity of breast and pancreatic tumor cells. We hypothesize that IL-13R␣2 chain may control vigorous growth of tumor cells in vivo. Tumor cells may grow faster if level of expression was decreased or this chain was not expressed at all. Alternatively, constitutive expression of IL-13R␣2 chain in tumor cells may recruit Th2 cells that predominantly produce IL-13, which may help escape immune surveillance and tumor development in immunocompetent hosts. Additional studies are warranted to further unravel the mechanism of inhibition of tumor growth and exact function of IL-13R␣2 chain in the context of tumor biology.
